Does anybody see IPIX licensing out an INDUSTRIAL partnership for Brilacidin for the myriad industrial applications of B? This would include paints, textiles, bandages, medical supplies, medical equipment and tools, plastics, etc? I ask this as these are mainly outside the realm of medicine and being a polymer whereas the medical applications use the small molecule form of the drug there should be no overlap.

Could the industrial side be spun off as another company so that should Leo decide to sell the company the industrial applications of B would not be part of the sale? IMO this could be quite large but currently nobody has any clue as to how to value it or whether it really does have a large value.

How would others handle this situation? This scenario gives all a chance to play Leo. I personally would spin the industrial (polymer) application of B into another company and immediately partner with a large industrial partner where our company gets royalties and the partner carries the entire load as to developmental costs. They could sub-partner out the polymer to leaders in each field (paints, bandages, IV equipment, plastics, etc) and collect royalties and then out of these they pay us our share. That way we assume no risk but potentially large royalties. Our company is basically a shell owning only the patent for the industrial B polymer. Or we could have one employee licensing out the product to individual partners in the various fields and get the royalty direct from them and cut out one level of additional royalty payments. The upfront payments for the licenses would pay for the employee so that there is basically no cost and no risk for this small, shell type company that only owns the patent to the industrial B polymer.